Novel, Anti-hTNF-&#945; Variable New Antigen Receptor Formats with Enhanced Neutralizing Potency and Multifunctionality, Generated for Therapeutic Development.

Ubah, Obinna C; Steven, John; Kovaleva, Marina; Ferguson, Laura; Barelle, Charlotte; Porter, Andrew J R; Barelle, Caroline J

Novel, Anti-hTNF-α Variable New Antigen Receptor Formats with Enhanced Neutralizing Potency and Multifunctionality, Generated for Therapeutic Development.

Ubah, Obinna C; Steven, John; Kovaleva, Marina; Ferguson, Laura; Barelle, Charlotte; Porter, Andrew J R; Barelle, Caroline J.

Afiliação

Ubah OC; Elasmogen Ltd., Aberdeen, Scotland.
Steven J; Elasmogen Ltd., Aberdeen, Scotland.
Kovaleva M; Elasmogen Ltd., Aberdeen, Scotland.
Ferguson L; Elasmogen Ltd., Aberdeen, Scotland.
Barelle C; Elasmogen Ltd., Aberdeen, Scotland.
Porter AJR; Elasmogen Ltd., Aberdeen, Scotland.
Barelle CJ; Scottish Biologics Facility, Institute of Medical Sciences, University of Aberdeen, Aberdeen, Scotland.

Front Immunol ; 8: 1780, 2017.

Article em En | MEDLINE | ID: mdl-29312310

Palavras-chave

anti-TNF biologics; bi-paratopic/bi-specific binding domain; chronic inflammation; cytokine neutralization; phage display; shark IgNAR; tumor necrosis factor-α; variable new antigen receptor

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Ano de publicação: 2017 Tipo de documento: Article